Savara (NASDAQ:SVRA) Stock Rating Reaffirmed by JMP Securities

Savara (NASDAQ:SVRA)‘s stock had its “market outperform” rating restated by equities research analysts at JMP Securities in a research note issued to investors on Tuesday, Benzinga reports. They currently have a $9.00 price objective on the stock. JMP Securities’ target price would indicate a potential upside of 120.05% from the stock’s previous close.

Several other research analysts also recently commented on SVRA. Oppenheimer raised their price objective on Savara from $11.00 to $15.00 and gave the stock an “outperform” rating in a research note on Wednesday, June 26th. HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Savara in a research note on Tuesday. Finally, Guggenheim lifted their price target on shares of Savara from $8.00 to $10.00 and gave the company a “buy” rating in a report on Thursday, June 27th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $11.17.

Savara Stock Performance

SVRA stock traded down $0.15 during midday trading on Tuesday, reaching $4.09. 108,586 shares of the company’s stock traded hands, compared to its average volume of 1,206,058. The company has a current ratio of 11.31, a quick ratio of 11.31 and a debt-to-equity ratio of 0.26. Savara has a 52-week low of $3.12 and a 52-week high of $5.70. The stock has a market cap of $565.19 million, a P/E ratio of -11.05 and a beta of 0.97. The stock’s 50-day moving average is $4.33 and its 200 day moving average is $4.46.

Savara (NASDAQ:SVRA) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.01). As a group, analysts anticipate that Savara will post -0.44 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Bain Capital Life Sciences Investors LLC grew its holdings in Savara by 2.3% during the 1st quarter. Bain Capital Life Sciences Investors LLC now owns 14,565,457 shares of the company’s stock valued at $72,536,000 after buying an additional 332,706 shares in the last quarter. Jennison Associates LLC increased its holdings in Savara by 0.3% in the 1st quarter. Jennison Associates LLC now owns 8,841,971 shares of the company’s stock valued at $44,033,000 after acquiring an additional 26,613 shares during the last quarter. Frazier Life Sciences Management L.P. lifted its stake in Savara by 103.9% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 8,157,385 shares of the company’s stock worth $32,874,000 after purchasing an additional 4,157,385 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of Savara by 2.5% during the 1st quarter. Vanguard Group Inc. now owns 6,063,620 shares of the company’s stock valued at $30,197,000 after purchasing an additional 148,673 shares during the last quarter. Finally, Nantahala Capital Management LLC boosted its holdings in shares of Savara by 198.2% during the 2nd quarter. Nantahala Capital Management LLC now owns 5,180,951 shares of the company’s stock valued at $20,879,000 after purchasing an additional 3,443,541 shares during the last quarter. 87.93% of the stock is owned by hedge funds and other institutional investors.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.